Jonathan Mc Neill Dyne Therapeutics, Inc. (DYN) insider trading activity

Jonathan Mc Neill is Chief Business Officer of Dyne Therapeutics, Inc.. Currently has a direct ownership of 132,106 shares of DYN, which is worth approximately $3.23 Million. The most recent transaction as insider was on Aug 19, 2024, when has been sold 2,705 shares (Common Stock) at a price of $45.5 per share, resulting in proceeds of $123,077. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 132K

0% 3M change

15.05% 12M change

Total Value Held $3.23 Million

Jonathan McNeill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 19 2024	SELL Open market or private sale	$123,077 $45.5 p/Share	2,705 Reduced 2.01%	132,106 Common Stock
Jun 11 2024	SELL Open market or private sale	$57,132 $31.34 p/Share	1,823 Reduced 1.33%	134,811 Common Stock
May 16 2024	SELL Open market or private sale	$78,781 $28.4 p/Share	2,774 Reduced 1.99%	136,634 Common Stock
Mar 11 2024	SELL Open market or private sale	$501,589 $25.59 p/Share	19,601 Reduced 12.33%	139,408 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	$98,750 $5.54 p/Share	17,825 Added 10.08%	159,009 Common Stock
Mar 08 2024	SELL Open market or private sale	$2,385,000 $26.5 p/Share	90,000 Reduced 38.93%	141,184 Common Stock
Mar 08 2024	BUY Exercise of conversion of derivative security	$498,600 $5.54 p/Share	90,000 Added 28.02%	231,184 Common Stock
Mar 07 2024	SELL Open market or private sale	$62,918 $25.85 p/Share	2,434 Reduced 1.69%	141,184 Common Stock
Mar 01 2024	SELL Open market or private sale	$703,540 $29.0 p/Share	24,260 Reduced 14.45%	143,618 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$17,709 $0.73 p/Share	24,260 Added 12.63%	167,878 Common Stock
Feb 29 2024	SELL Open market or private sale	$117,370 $27.5 p/Share	4,268 Reduced 2.89%	143,618 Common Stock
Feb 29 2024	BUY Exercise of conversion of derivative security	$3,115 $0.73 p/Share	4,268 Added 2.81%	147,886 Common Stock
Jan 26 2024	SELL Open market or private sale	$496,599 $24.83 p/Share	20,000 Reduced 12.22%	143,618 Common Stock
Jan 26 2024	BUY Exercise of conversion of derivative security	$14,600 $0.73 p/Share	20,000 Added 10.89%	163,618 Common Stock
Jan 04 2024	SELL Open market or private sale	$36,242 $18.04 p/Share	2,009 Reduced 1.38%	143,618 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	$1,466 $0.73 p/Share	2,009 Added 1.36%	145,627 Common Stock
Jan 03 2024	SELL Open market or private sale	$336,251 $18.69 p/Share	17,991 Reduced 11.13%	143,618 Common Stock
Jan 03 2024	BUY Exercise of conversion of derivative security	$13,133 $0.73 p/Share	17,991 Added 10.02%	161,609 Common Stock
Jan 02 2024	SELL Open market or private sale	$155,890 $13.1 p/Share	11,900 Reduced 7.65%	143,618 Common Stock
Dec 11 2023	SELL Open market or private sale	$13,346 $10.72 p/Share	1,245 Reduced 0.79%	155,518 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	-	96,158 Added 38.02%	156,763 Common Stock
Sep 18 2023	SELL Open market or private sale	$11,866 $9.41 p/Share	1,261 Reduced 2.04%	60,605 Common Stock
Sep 12 2023	SELL Open market or private sale	$13,179 $10.41 p/Share	1,266 Reduced 2.01%	61,866 Common Stock
Jun 13 2023	SELL Open market or private sale	$15,649 $12.43 p/Share	1,259 Reduced 1.96%	63,132 Common Stock
Jun 12 2023	SELL Open market or private sale	$13,000 $13.0 p/Share	1,000 Reduced 1.53%	64,391 Common Stock

Jonathan Mc Neill

Chief Business Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DYN shares.

Notify only if

Value

Insider Trading

Get notified when an Dyne Therapeutics, Inc. insider buys or sells DYN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Dyne Therapeutics, Inc.

Track Activities on DYN

Account